CD274 and breast carcinoma: Similarly, in breast cancer, the KEYNOTE‐355 trial confirmed that for metastatic TNBC, pembrolizumab combined with chemotherapy confers enhanced clinical benefit in patients with PD‐L1‐positive tumors [89].